Either B-type natriuretic peptide (BNP) or NT-proBNP may be used as a diagnostic, screening, prognostic and therapeutic tool for CHF. The Food and Drug Administration (FDA) cleared the cut-off point for BNP at 100 pg/ mL, and that of NT-proBNP at 125 pg/mL for patients <75 years and 450 pg/mL for those >75. A steadily rising titre even below the cut-off value should be raised as a concern as heart failure is progressive if left untreated and may result in cardiac death. Both biomarkers are also featured in lab investigations for patients with acute coronary syndrome (ACS).
INtrodUCtIoN
This article provides insights into a frequently requested test for the less initiated. This brief review will be limited to B-type natriuretic peptide (BNP) and N-terminal BNP propeptide (NT-proBNP). There is some interest in atrial natriuretic peptide (ANP) measurements in countries like Japan where the recombinant ANP (carperitide) has been approved for intravenous administration in patients with acute heart failure. 1 bNP and Nt-probNP ProBNP is released from the cardiac ventricles in response to pressure or volume overload of the ventricles. 2, 3 It is enzymatically cleaved to form BNP and NT-proBNP. BNP, composed of 32 amino acids, is the active hormone and moderates the secretion of renin, angiotensin II and aldosterone while the 76 amino acid NT-proBNP is biologically inert. 4 sPeCImeN Either serum or plasma (heparinised or EDTA) may be used and should be assayed immediately for optimal results.
INdICAtIoNs
Natriuretic peptides may be used as screening, diagnostic, prognostic and therapeutic tools in congestive heart failure (CHF).
screening tool BNP or NT-proBNP provides a quick and useful means for triaging dypsneic patients and making appropriate referrals to either a pulmonologist or cardiologist. Incorporating BNP into the clinical evaluation of CHF helps clarify cardiac from pulmonary diseases (including asthma, COPD, interstitial lung disease, pneumoconiosis and hypercapnic respiratory failure), 5 and has been shown to improve the diagnostic accuracy by as much as 10% in the Breathing Not Properly (BNP) multinational study. 6
diagnostic tool
The European Society of Cardiology (ESC) 7 and National Academy of Clinical Biochemistry (NACB) 8 have listed BNP and NT-proBNP as appropriate diagnostic tests to confirm or rule out the diagnosis of heart failure. Both biomarkers are useful for urgent diagnosis or exclusion of acute congestive heart failure as it is very improbable at BNP <100 pg/mL or NT-proBNP <300-400 pg/mL but highly probable at BNP >400-500 pg/mL or NT-proBNP >1800-2000 pg/mL. 7, [9] [10] [11] [12] The ICON study group has stratified the optimal rule-in cut-off of NT-proBNP by age: <50 years (>450 pg/mL), 50-75 years (>900 pg/mL) and >75 years (>1800 pg/mL). 13 Results from the ICON study 14 demonstrates the value of NT-proBNP for the diagnosis and exclusion of acute HF since age stratification improves the diagnostic sensitivity in younger patients, while preserving the specificity of the test for older subjects.
Prognostic tool
BNP and NT-ProBNP may be used synergistically with cardiac troponins for risk stratification in cardiac disease as increased values indicate worse haemodynamics and hence a worse prognosis. 2, 15 Patients who died or were rehospitalised tended to have an increase in their BNP concentration while those who were successfully treated tended to have decreases in their BNP concentrations during hospitalisation. 16, 17 The ICON study demonstrates the value of NT-proBNP for predicting the likelihood for short-term mortality in subjects with acute heart failure (AHF), with a more than five-fold increase in risk for death by 76 days among those with marked elevations in NT-proBNP concentrations. 14 It has been reported that BNP levels may help identify decompensated patients who are most likely to be re-hospitalised. 18 In any case, a rising titre even below the recommended cut-off values should raise concern as left ventricular dysfunction is progressive if left untreated and may result in cardiac death.
Increased levels of BNP and NT-ProBNP have also been linked to critically ill patients in intensive care and with worse prognosis 19 , including acute respiratory failure, 20 severe sepsis or septic shock, 21 with various cardiovascular diseases 22 but this knowledge has limited clinical application unless evidence-based guidelines on how to interpret the results for managing these patients are documented.
therapeutic Guide BNP and NT-ProBNP may be used as therapy guides since repeated measurements of the same biomarker over time convey incremental prognostic information and hence the opportunity for titrating medical therapies accordingly such as pharmacotherapy (angiotensin-converting enzyme inhibitors, beta-blockers, diuretics), 23, 24 haemodynamic titration, 25 and cardiac resynchronisation with biventricular pacemaker 26 as BNP levels have been shown to be well correlated to clinical outcomes. However, the reference change value (sum of analytical and intra-individual variance) in serial determinations must be interpreted with the biologic variation in view of the high week-to-week intraindividual variation for BNP and NT-proBNP of up to 33% to 60%. 2, 27 A synthesis of data available from New Zealand projects (STARS-BNP 23 , STARBRITE 28 , TIME-CHF 29 , BATTLESCARRED and PRIMA) concluded that despite their limitations, the weight of the available evidence suggests that a natriuretic-peptideguided approach could reduce hospitalizations for heart failure in patients below 75 years of age. 4
AssAy methods
Both BNP and NT-proBNP are measured using immunometric sandwich assays on either fully automated or point-of-care platforms. A comparative study of NT-proBNP and BNP shows similar diagnostic accuracy and clinical relevance of both acute and chronic HF patients. 30 It must be noted the imprecision of point-of-care instruments are higher than the automated platforms. 27 The FDA has cleared BNP and NT-proBNP assays to aid in the diagnosis and assessment of the severity of heart failure and for risk stratification of ACS. The FDA-cleared cut-off for BNP is 100 pg/mL while that of NT-proBNP is 125 pg/mL for patients <75 years and 450 pg/mL for those over 75. 3 There are certain advantages to measuring NT-proBNP over BNP, chief of which is that age-related cut-offs are available. 9, 31 Plasma concentrations of NT-proBNP is 20 times that of BNP since its in vivo half-life is one to two hours versus 20 to 21 minutes for BNP. 2, 3 NT-proBNP has an in vitro stability of 48 hours at room temperature while that of BNP is four to eight hours. 3 While BNP levels may be falsely elevated in CHF patients receiving therapeutic BNP (Nesiritide/ Natrecor), 32 NT-proBNP measurements are unaffected. NT-proBNP values obtained in different vendor assays concur as antibodies and calibrators are provided by a single vendor (Roche) while BNP values may show methodological differences due to non-standardisation among the different vendors. NT-proBNP reagents are utilized by Roche, Siemens (Dade Behring, Diagnostics Products Corporation), Ortho Clinical Diagnostics, and BioMerieux. The BNP reagents formulated by Shionogi, Scios and Biosite are adopted by Abbott, Beckman Coulter, Inverness and Siemens (Advia). 2 Also, the reference change value of NT-proBNP is Proceedings of Singapore Healthcare  Volume 20  Number 4  2011 lower than BNP, suggesting it is a more sensitive marker in serial measurements. 27 refereNCe VAlUes With the Abbott BNP assay, we observed that many patients have values below the lower limit of detection of 10 pg/mL. Thus we conducted a large reference range study (n=1157) in our local population. The NP values were highly skewed to the right in both genders and were below the assay detection limit in 85.4% of males and 81.1% of females. The 95th and 97.5th percentile cut-offs for 591 males (age 35-74, mean 50) was 16.4 pg/ mL and 21.1 pg/mL respectively; in 566 females (age 40-74, mean 53.6) the cut-offs were 21.7 and 25.7 pg/mL. There is paucity of NP reference range data in Asian populations. Thus, the rule-in rule-out decision limits for AHF for Asians might need to be revisted in local studies.
lImItAtIoNs
Natriuretic peptide results should be interpreted in conjunction with the patient's medical history, clinical examination and other findings. It must be emphasised that a value below the recommended cut-off does not completely exclude CHF but suggests that heart failure is unlikely. Besides heart failure, BNP and NT-proBNP are also elevated in conditions such as inflammatory cardiac diseases, systemic arterial hypertension with left ventricular hypertrophy, pulmonary hypertension, acute or chronic renal failure, ascitic liver cirrhosis and some endocrine disorders. 8 BNP and NT-proBNP results are higher in females and increase with age in both genders, age-33 and gender 34 -specific reference intervals should be considered in results interpretation. The biologic variability is sufficiently high that values should change by 50% to 100% to be certain that the NP changes in a patient are significant. NT-proBNP may be falsely elevated in severe renal disease as it is thought to be primarily cleared by kidneys. Lower-than-expected levels may be obtained in patients co-presenting with obesity, acute pulmonary oedema, mitral stenosis and acute mitral regurgitation. The literature on the extended use of NPs is expanding to include acute chest pain, 35 myocardial infarction, 36 stress-induced myocardial ischaemia, 37 cardiac dysfunction in sepsis, 38 as well as preoperative 39 and postoperative 40 
